Drug Profile
Hydroxychloroquine/Ribavirin - BioLineRx
Alternative Names: BL 8020; Ribavirin/hydroxychloroquineLatest Information Update: 24 Dec 2019
Price :
$50
*
At a glance
- Originator Genoscience
- Developer BioLineRx
- Class Antimalarials; Antivirals; Quinolines; Ribonucleosides; Small molecules
- Mechanism of Action Autophagy inhibitors; Phospholipase A2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Hepatitis C
Most Recent Events
- 24 Dec 2019 Discontinued - Phase-I/II for Hepatitis C in France (PO) (BioLineRx website, December 2019)
- 15 Feb 2016 Phase-I/II development is ongoing in France (PO)
- 17 Mar 2014 BioLineRx enters into a global collaboration agreement covering the transfer of development rights to Genoscience and Panmed